BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 27219686)

  • 1. Diabetes and Cancer: a Review of Current Knowledge.
    Wojciechowska J; Krajewski W; Bolanowski M; Kręcicki T; Zatoński T
    Exp Clin Endocrinol Diabetes; 2016 May; 124(5):263-75. PubMed ID: 27219686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives.
    Vrachnis N; Iavazzo C; Iliodromiti Z; Sifakis S; Alexandrou A; Siristatidis C; Grigoriadis C; Botsis D; Creatsas G
    Arch Gynecol Obstet; 2016 Feb; 293(2):239-46. PubMed ID: 26338721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study.
    Lin CM; Huang HL; Chu FY; Fan HC; Chen HA; Chu DM; Wu LW; Wang CC; Chen WL; Lin SH; Ho SY
    PLoS One; 2015; 10(5):e0125421. PubMed ID: 25978841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 Diabetes Mellitus and Its Association with the Risk of Pancreatic Carcinogenesis: A Review.
    Biadgo B; Abebe M
    Korean J Gastroenterol; 2016 Apr; 67(4):168-77. PubMed ID: 27112242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].
    Ozawa H; Murai Y; Ozawa T
    Yakushigaku Zasshi; 2003; 38(1):11-27. PubMed ID: 14570054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment.
    Suh S; Kim KW
    Diabetes Metab J; 2019 Dec; 43(6):733-743. PubMed ID: 31902143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes mellitus: influences on cancer risk.
    Szablewski L
    Diabetes Metab Res Rev; 2014 Oct; 30(7):543-53. PubMed ID: 25044584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risks from diabetes therapies: evaluating the evidence.
    Li C; Kong D
    Pharmacol Ther; 2014 Oct; 144(1):71-81. PubMed ID: 24844968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of metformin on the incidence of head and neck cancer in diabetics.
    Yen YC; Lin C; Lin SW; Lin YS; Weng SF
    Head Neck; 2015 Sep; 37(9):1268-73. PubMed ID: 24801563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and perspectives in the treatment of diabetes associated breast cancer.
    Samuel SM; Varghese E; Varghese S; Büsselberg D
    Cancer Treat Rev; 2018 Nov; 70():98-111. PubMed ID: 30130687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New clinical data with metformin therapy in patients with diabetes mellitus].
    Jermendy G
    Orv Hetil; 2010 Dec; 151(49):2025-30. PubMed ID: 21106483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
    Kowall B; Stang A; Rathmann W; Kostev K
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Biology and Prevention in Diabetes.
    Srivastava SP; Goodwin JE
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin: risk-benefit profile with a focus on cancer.
    Provinciali N; Lazzeroni M; Cazzaniga M; Gorlero F; Dunn BK; DeCensi A
    Expert Opin Drug Saf; 2015 Oct; 14(10):1573-85. PubMed ID: 26359221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer.
    Raguraman R; Srivastava A; Munshi A; Ramesh R
    Adv Drug Deliv Rev; 2021 Nov; 178():113918. PubMed ID: 34375681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients.
    Sciacca L; Vigneri R; Tumminia A; Frasca F; Squatrito S; Frittitta L; Vigneri P
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):808-15. PubMed ID: 23932729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    Rieken M; Xylinas E; Kluth L; Trinh QD; Lee RK; Fajkovic H; Novara G; Margulis V; Lotan Y; Martinez-Salamanca JI; Matsumoto K; Seitz C; Remzi M; Karakiewicz PI; Scherr DS; Briganti A; Kautzky-Willer A; Bachmann A; Shariat SF;
    Eur J Surg Oncol; 2014 Jan; 40(1):113-20. PubMed ID: 24113620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Fajkovic H; Babjuk M; Kautzky-Willer A; Bachmann A; Scherr DS; Shariat SF
    BJU Int; 2013 Dec; 112(8):1105-12. PubMed ID: 24053906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort.
    Baur DM; Klotsche J; Hamnvik OP; Sievers C; Pieper L; Wittchen HU; Stalla GK; Schmid RM; Kales SN; Mantzoros CS
    Metabolism; 2011 Oct; 60(10):1363-71. PubMed ID: 21081242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.